NasdaqGS - Delayed Quote • USD
DexCom, Inc. (DXCM)
At close: 4:00 PM EDT
After hours: 6:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 21 | 21 |
| Avg. Estimate | 0.27 | 0.39 | 1.76 | 2.24 |
| Low Estimate | 0.21 | 0.36 | 1.64 | 2.03 |
| High Estimate | 0.34 | 0.44 | 1.88 | 2.51 |
| Year Ago EPS | 0.17 | 0.34 | 1.52 | 1.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 24 | 24 |
| Avg. Estimate | 909.24M | 1.05B | 4.33B | 5.15B |
| Low Estimate | 877.65M | 1.02B | 4.26B | 4.99B |
| High Estimate | 928M | 1.08B | 4.37B | 5.3B |
| Year Ago Sales | 720.74M | 841.62M | 3.62B | 4.33B |
| Sales Growth (year/est) | 26.20% | 24.30% | 19.40% | 19.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.15 | 0.23 | 0.34 | 0.43 |
| EPS Actual | 0.17 | 0.34 | 0.5 | 0.5 |
| Difference | 0.02 | 0.11 | 0.16 | 0.07 |
| Surprise % | 13.30% | 47.80% | 47.10% | 16.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.27 | 0.39 | 1.76 | 2.24 |
| 7 Days Ago | 0.27 | 0.39 | 1.76 | 2.24 |
| 30 Days Ago | 0.27 | 0.39 | 1.75 | 2.23 |
| 60 Days Ago | 0.27 | 0.39 | 1.75 | 2.23 |
| 90 Days Ago | 0.28 | 0.4 | 1.72 | 2.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DXCM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 58.80% | -- | -- | 2.60% |
| Next Qtr. | 14.70% | -- | -- | 13.40% |
| Current Year | 15.80% | -- | -- | 5.20% |
| Next Year | 27.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 33.40% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 31.86% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | UBS: Buy to Buy | 4/10/2024 |
| Maintains | Citigroup: Buy to Buy | 4/3/2024 |
| Initiated | RBC Capital: Outperform | 3/12/2024 |
| Maintains | Raymond James: Strong Buy to Strong Buy | 1/23/2024 |
| Maintains | Raymond James: Strong Buy to Strong Buy | 1/3/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 12/19/2023 |
Related Tickers
PODD Insulet Corporation
164.17
-1.84%
TNDM Tandem Diabetes Care, Inc.
35.56
+1.25%
ALGN Align Technology, Inc.
310.50
-1.05%
EW Edwards Lifesciences Corporation
88.01
-0.68%
BSX Boston Scientific Corporation
73.26
+0.48%
ABT Abbott Laboratories
106.86
-0.03%
SWAV Shockwave Medical, Inc.
328.99
+0.04%
INSP Inspire Medical Systems, Inc.
231.01
-1.36%
MDT Medtronic plc
79.25
-1.41%
TMDX TransMedics Group, Inc.
89.25
+0.42%